3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Neoplasms
3
Melanoma
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor - Protocol Specific
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hypertension
1
Glioblastoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
24
Paclitaxel
11
Carboplatin
11
Trastuzumab
9
Nivolumab
7
Fulvestrant
6
palbociclib
4
olaparib
4
Taxes
4
Surveys and Questionnaires
4
Methods
4
Early Intervention, Educational
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
pertuzumab
3
lenvatinib
3
fludarabine
3
atezolizumab
3
abemaciclib
3
Tamoxifen
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Metformin
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interviews as Topic
3
Gemcitabine
3
Counseling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
pazopanib
×
Breast
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled